Xeris Pharmaceuticals
XERS
10.11
+0.04
+0.40%
Xeris Pharmaceuticals
US · XERS
#2862 by market cap
Listed 2018
10.11
+0.04
+0.40%
Live - 5344 symbols - heartbeat 557s ago
· 2026-10-08 07:22
Pre-market
10.04
-0.69%
After-hours
10.00
-1.09%
- Market cap
- 1.84B
- P/E (TTM)i
- -104.23
- P/Bi
- -190.75
- EPSi
- 0.00
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on XERS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.92, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +43.72% YoY
Margins
- Gross margin
- 85.41%
- Operating margin
- 8.53%
- Net margin
- 0.19%
Key ratios & quality
- Enterprise valuei
- 1.96B
- Altman Z-Scorei
- 1.92
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 20.44M | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M |
| Gross profit | 2.42M | 1.12M | 11.11M | 36.27M | 87.61M | 135.27M | 166.24M | 249.28M |
| Selling & admin expenses | 21.11M | 63.06M | 73.73M | 125.72M | 137.75M | 146.10M | 163.48M | 182.37M |
| Research & development | 40.65M | 60.44M | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M | 31.17M |
| Operating profit | -59.34M | -122.38M | -83.55M | -115.16M | -81.94M | -44.01M | -33.65M | 24.90M |
| Pretax profit | -60.08M | -126.04M | -91.25M | -122.73M | -96.08M | -63.50M | -57.10M | 554.00K |
| Tax | 0 | -458.00K | -110.00K | 0 | -1.42M | -1.25M | -2.27M | 0 |
| Net profit | -60.08M | -125.58M | -91.14M | -122.73M | -94.66M | -62.26M | -54.84M | 554.00K |
| Basic EPS | -5 | -5 | -2 | -2 | -1 | 0 | 0 | 0 |
| Diluted EPS | -4.99 | -4.81 | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 | 0.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 60.12M | 71.54M | 74.38M | 85.81M | 83.13M | 92.10M |
| Gross profit | 51.39M | 59.64M | 63.38M | 74.86M | 72.55M | 79.59M |
| Selling & admin expenses | 44.02M | 44.39M | 46.46M | 47.50M | 53.14M | 61.04M |
| Research & development | 7.75M | 8.06M | 7.48M | 7.87M | 8.78M | 10.67M |
| Operating profit | -3.09M | 4.48M | 6.73M | 16.77M | 7.92M | 5.17M |
| Pretax profit | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | -31.10M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | -31.10M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.06 | -0.01 | 0.00 | 0.06 | 0.01 | -0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 117.90M | 87.48M | 152.21M | 142.60M | 186.82M | 156.26M | 167.66M | 240.31M |
| Cash & ST investments | 112.63M | 75.55M | 133.79M | 102.43M | 121.97M | 72.45M | 71.62M | 111.04M |
| Inventory | 0 | 2.18M | 8.35M | 18.12M | 24.74M | 38.84M | 48.18M | 68.67M |
| Total assets | 120.03M | 108.99M | 159.15M | 304.36M | 344.52M | 322.60M | 323.06M | 383.53M |
| Total current liabilities | 10.17M | 27.34M | 28.21M | 79.04M | 73.62M | 95.19M | 100.44M | 109.57M |
| Short-term debt | -- | -- | -- | -- | 1.58M | 3.50M | 21.18M | 6.23M |
| Long-term debt | 31.89M | 58.31M | 87.02M | 88.07M | 187.08M | 190.93M | 217.01M | 220.34M |
| Total liabilities | 44,622,000.00 | 94,551,000.00 | 125,390,000.00 | 209,130,000.00 | 299,335,000.00 | 329,384,000.00 | 352,675,000.00 | 369,838,000.00 |
| Total equity | 75.41M | 14.44M | 33.76M | 95.23M | 45.19M | -6.78M | -29.62M | 13.69M |
| Retained earnings | -120.67M | -246.25M | -337.39M | -460.11M | -554.77M | -617.03M | -671.86M | -671.31M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 163.49M | 185.58M | 224.02M | 240.31M | 251.68M | 274.76M |
| Cash & ST investments | 58.44M | 59.29M | 91.60M | 111.04M | 111.75M | 121.75M |
| Inventory | 52.69M | 67.28M | 67.46M | 68.67M | 74.23M | 80.93M |
| Total assets | 315.45M | 334.69M | 370.19M | 383.53M | 392.01M | 411.91M |
| Total current liabilities | 95.07M | 95.17M | 116.20M | 109.57M | 118.59M | 189.57M |
| Short-term debt | 18.08M | 6.16M | 6.19M | 6.23M | 6.27M | 70.09M |
| Long-term debt | 217.81M | 218.63M | 219.47M | 220.34M | 221.22M | 188.81M |
| Total liabilities | 350,581,000.00 | 353,990,000.00 | 371,052,000.00 | 369,838,000.00 | 379,002,000.00 | 421,639,000.00 |
| Total equity | -35.13M | -19.30M | -861.00K | 13.69M | 13.01M | -9.73M |
| Retained earnings | -681.08M | -683.01M | -682.39M | -671.31M | -669.07M | -700.17M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -56.28M | -104.35M | -80.56M | -95.54M | -102.89M | -47.02M | -36.98M | 28.63M |
| Depreciation & amortization | 320.00K | 1.08M | 1.47M | 1.88M | 12.67M | 13.16M | 12.63M | 12.69M |
| Free cash flow | -57.79M | -105.45M | -80.94M | -96.62M | -103.42M | -49.29M | -37.85M | 27.93M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 98.33M | 61.69M | 65.83M | 26.47M | 29.53M | -1.01M | -3.73M | -1.71M |
| Ending cash balance | 45.72M | 19.52M | 37.60M | 67.27M | 126.31M | 71.67M | 75.74M | 115.06M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -10.03M | 182.00K | 18.43M | 20.04M | 9.87M | 8.26M |
| Depreciation & amortization | 3.14M | 3.16M | 3.19M | 3.20M | 3.21M | 3.21M |
| Free cash flow | -10.04M | -97.00K | 18.36M | 19.71M | 9.55M | 8.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -8.00M | -860.00K | -478.00K | 7.63M | -9.68M | 409.00K |
| Ending cash balance | 62.56M | 63.41M | 95.62M | 115.06M | 115.77M | 125.77M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -683.66 | -279.56 | -378.20 | -190.28 | -134.83 | -324.20 | -- | -- |
| ROA %i | -72.81 | -109.67 | -67.98 | -52.95 | -29.18 | -18.66 | -16.99 | 0.16 |
| ROIC %i | -145.41 | -134.69 | -86.25 | -76.20 | -38.35 | -17.54 | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -333.30 | -261.41 | -- | -- |
| EBIT margin %i | -2,334.08 | -4,367.19 | -394.37 | -233.00 | -73.25 | -22.51 | -13.11 | 10.16 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 9.57 |
| Current ratioi | 11.59 | 3.20 | 5.40 | 1.80 | 2.54 | 1.64 | 1.67 | 2.19 |
| Quick ratioi | 11.35 | 2.94 | 4.99 | 1.52 | 2.08 | 1.17 | 1.12 | 1.48 |
| Debt / assetsi | 26.57 | 53.50 | 54.68 | 28.94 | 57.49 | 71.04 | 84.02 | 67.30 |
| LT debt / equityi | 42.29 | 403.89 | 257.76 | 92.48 | 434.81 | -- | -- | 1,839.92 |
| Interest coveragei | -22.61 | -16.60 | -7.56 | -16.09 | -5.27 | -1.39 | -0.87 | 1.02 |
| Revenue CAGR (3Y) %i | -- | 36.30 | 135.93 | 173.54 | 243.42 | 100.18 | 59.99 | 38.33 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -13.83 | -9.60 | -4.52 | 0.16 | 3.39 | -4.60 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -7.59 | -2.10 | 5.26 | 10.16 | 12.92 | 3.31 |
| FCF / sales %i | -- | -- | 3.75 | 9.57 | 15.09 | 16.60 |
| Current ratioi | 1.72 | 1.95 | 1.93 | 2.19 | 2.12 | 1.45 |
| Quick ratioi | 1.10 | 1.18 | 1.25 | 1.48 | 1.42 | 0.95 |
| Debt / assetsi | 85.20 | 76.86 | 69.60 | 67.30 | 65.96 | 70.27 |
| LT debt / equityi | -- | -- | -- | 1,839.92 | 1,938.99 | -- |
| Interest coveragei | -0.55 | -0.17 | 0.47 | 1.02 | 1.42 | 0.39 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Recorlev is the largest reported line at 61.65% of revenue, across 4 reported segments.
- Gvoke follows at 24.48%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Recorlev61.65%
Gvoke24.48%
Keveyis12.68%
Royalty, contract and other revenue1.19%
Quote time 2026-10-08 07:22:20 · For reference only, not investment advice and not tailored to your situation.